SALSA: Self-Administered Lidocaine Gel for Pain Management with First Trimester Surgical Abortion A Randomized Trial Paul D Blumenthal, MD, MPH



Stanford University Medical Center





Background

- Pain is a limiting factor in where and how abortion is performed
 - ACCESS issue
 - Pain management has not been woman centered
- 84% of providers employ a lidocaine paracervical block (PCB)
 - Non-standardized approach
 - PCB itself can be painful





Clinical Question

- Can we achieve adequate pain relief through self-administered, non-invasive means alone?
- Should we wait longer between lidocaine administration and procedure start time?



Study Objectives



- To compare pain control using a locallyapplied, <u>self-administered</u> lidocaine gel with PCB
- To increase pain control options
- <u>Hypothesis:</u>

Patients who receive lidocaine gel applied 20-30 minutes prior to first trimester surgical abortion will have pain control that is *no worse than* that of a traditional paracervical block





Study Design

- Open label, RCT
- Non-inferiority design
- 20ml of 2% lidocaine HCl vaginally (400mg) 20-30 minutes prior to procedure






Study Design



Paracervical Block Technique:

- 12 mL of 1% lidocaine (120 mg) with epinephrine
- 2 mL injected at tenaculum site
- Tenaculum immediately placed
- 10 mL injected into cervicovaginal junction at 4 and 8 o'clock





Lidocaine Dose




- Serum toxicity of intracervical lidocaine: 5 mcg/ml [Blanco 1982]
- Serum lidocaine levels 10 minutes after paracervical injection of 20 ml of 1% lidocaine (200mg) found mean blood levels of 0.9 to 1.61 mcg/ml [McKenzie 1978]
- Serum lidocaine levels following 4ml of 10% lidocaine spray (400mg) prior to intracavitary vaginal brachytherapy found non-toxic levels & adequate pain relief [Chen 1998]





Gel Protocol











Study Design

- Inclusion criteria
 - ≥ 18 years
 - •5 11w5d gestation
 - English or Spanish speaking
- Exclusion criteria
 - Preoperative misoprostol
 - PO pain medication instead of iv
 - Allergy to lidocaine, midazolam, fentanyl
 - Known uterine anomaly or cervical procedure
 - Inability to use tampons







Recruitment & Allocation

- Block randomization
- Intention to treat
- Open label
 - versus single blinded with (sham PCB + gel) and (PCB + KY jelly)
 - »Ineffective blinding (Renner, et al)



■

Outcomes

Primary Outcome:

Pain perceived by VAS (0-100 mm) at time of cervical dilation

Visual Analog Scale (VAS)*

No Pain

Worst pain imaginable



Outcomes



Secondary Outcomes:

Pain perceived at additional time points:

- Anticipated pain: 30 minutes prior to procedure
- -Baseline pain: arrival to procedure room
- -After speculum placement
- -After tenaculum placement
- At procedure completion, after speculum removal
- -In recovery: 30-45 minutes after procedure





Results: Demographics

• No significant differences between groups





	Lidocaine Paracervical Block <i>n</i> =68	Self-administered Lidocaine Gel <i>n=</i> 69	p value
4	<u> </u>	ł	-
Type of Procedure			.81*
MVA	59 (86.8%)	58 (84.1%)	
EVA	9 (13.2%)	11 (15.9%)	
Maximum Dilation (mm)			
Mean (±SD)	8.21±1.6	7.72±1.6	.09*
Median (Range)	8 (6-12)	7 (6-11)	.08 [†]
Time between gel insertion and speculum placement (min:seconds)			
Mean (\pm SD)		39:02±14:20	
Median (Range)		37:10 (15:00-86:00)	
Time between paracervical block and cervical dilation (min:seconds)			
Mean (±SD)	1:07±1:04		
Median (Range)	1:00 (0:20-4:00)		
Total Procedure Time (min:seconds)			
Median (Range)	7:16 (3:00-16:07)	5:23 (2:20-15:38)	.000†



^a Fisher's Exact Test
^b Student's *t* test



^c Mann-Whitney U-test






Figure 2. Box plot of pain scores (VAS) at various time points, medians displayed





	Median			Mean		
	PCB	Gel	p-	PCB	Gel	p-
	mm	mm	value	mm	mm	value
	(range)	(range)		(± S.D.)	(± S.D.)	
All Subjects	<i>n</i> =68	<i>n</i> =69		<i>n</i> =68	<i>n</i> =69	
Cervical Dilation	65	68	.45ª	60.12	64.07	.31 ^b
	(10-	(17-97)		(± 24.18)	(± 20.85)	
	100)					
Nulliparous	<i>n</i> =40	n=44		<i>n</i> =40	n=44	
Subjects						
Cervical Dilation	64.5	69	.24ª	58.15	65.57	.12 ^b
	(10-96)	(20-96)		(± 24.15)	(± 19.59)	
Parous Subjects	<i>n</i> =28	n=25		<i>n</i> =28	n=25	
Cervical Dilation	65.5	66	.86ª	62.93	61.44	.82 ^b
	(11-	(17-97)		(± 24.38)	(± 23.08)	
	100)					

^a Mann-Whitney U-test
^b Student's t test



Acceptability







· · · ·

Limitations

- Non-blinded
- Exclusion of PO sedation patients



Strengths



- Generalizability to other GYN procedures
 - Intra-Uterine Device insertions
 - Endometrial biopsies
 - Hysteroscopy

Part II: **SALUD** (Self-Administered Lidocaine for Uterine Devices)





Thank You

- Dr. Jennifer Conti
- Dr. Kate Shaw
- Klaira Lerma
- Corinne Montgomery









Questions?







▲ ●

References

- 1. Facts on Induced Abortion Worldwide. January 2012 [cited December 20, 2015]; Available from: http://www.guttmacher.org/pubs/fb_IAW.html
- 2. Facts on Induced Abortion in the United States. July 2014 [cited December 20, 2015]; Available from: http://www.guttmacher.org/pubs/fb_induced_abortion.html
- 3. Chapter 8: Pain Management. In: Paul M, Lichtenberg PM, Borgatta, L., Grimes, D., Sutbblefield, P. G., Creinin, M., editors. Management of unintended and abnormal pregnancy: Comprehensive abortion care. Hoboken, NJ: Blackwell Publishing, LTD; 2009. p. 90-110.
- 4. Belanger E, Melzack R, Lauzon P. Pain of first-trimester abortion: a study of psychosocial and medical predictors. Pain 1989 Mar;36(3):339-50.
- 5. Renner RM, Jensen JT, Nichols MD, Edelman AB. Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception 2010 May;81(5):372-88.
- 6. O'Connell K, Jones HE, Simon M, Saporta V, Paul M, Lichtenberg ES, et al. First-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception 2009 May;79(5):385-92.
- 7. Renner RM, Nichols MD, Jensen JT, Li H, Edelman AB. Paracervical block for pain control in first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol 2012 May;119(5):1030-7.
- 8. Li HW, Wong CY, Lo SS, Fan SY. Effect of local lignocaine gel application for pain relief during suction termination of first-trimester pregnancy: a randomized controlled trial. Hum Reprod 2006 Jun;21(6):1461-6.
- 9. Karasahin KE, Alanbay I, Ercan CM, Mesten Z, Simsek C, Baser I. Lidocaine spray in addition to paracervical block reduces pain during first-trimester surgical abortion: a placebo-controlled clinical trial. Contraception 2011 Apr;83(4):362-6.
- 10. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain 2003 Sep;4(7):407-14.
- 11. Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain 2001 Nov;94(2):131-2.
- 12. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med 1996 Apr;27(4):485-9.
- 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009 Apr;42(2):377-81.
- 14. Richardson SJ, Brooks HL, Bramley G, Coleman JJ. Evaluating the effectiveness of self-administration of medication (SAM) schemes in the hospital setting: a systematic review of the literature. PLoS One 2014;9(12):e113912.
- 15. Blanco LJ, Reid PR, King TM. Plasma lidocaine levels following paracervical infiltration for aspiration abortion. Obstet Gynecol 1982 Oct;60(4):506-8.
- 16. Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Huang EY, et al. Local vaginal anesthesia during high-dose-rate intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 1998 Oct 1;42(3):541-4.
- 17. McKenzie R, Shaffer WL. A safer method for paracervical block in therapeutic abortions. Am J Obstet Gynecol 1978 Feb 1;130(3):317-20.



Analysis




Statistical methods:

- Demographic characteristics compared using Chi-square test or Student's *t*-test
- Student's t-test to evaluate primary outcome of pain at cervical dilation
- Median VAS scores analyzed using nonparametric tests.
- Multivariate analyses to evaluate potential confounders and determine independent predictors of pain at the time of cervical dilation









■

Methods

Sample size calculation:

- –Delta = 15% difference in VAS*
- -Standard deviation of VAS = 26mm**
- $-\alpha$ =0.025 & β =0.10, 90% power
- -142 participants (71 per group)

